Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

thehindu.com -  The Hindu Bureau - VSU signs MoU with Malladi Drugs to make pharma students industry-ready
VSU signs MoU with Malladi Drugs to make pharma students industry-ready
The Hindu –

With the aim of providing students with quality education, technical knowledge and practical skills required in the pharmaceutical industry, Vikrama Simhapuri University (VSU), through its College of Pharmaceutical Sciences, Kavali, has entered…

seekingalpha.com - Edmund Ingham - Rhythm Pharma: Is AstraZeneca/Eli Lilly's Bidding War For Real? Don't Rule It Out
Rhythm Pharma: Is AstraZeneca/Eli Lilly's Bidding War For Real? Don't Rule It Out
Seeking Alpha –

I maintain a 'Hold' on Rhythm Pharmaceuticals, Inc.: takeover upside is credible, but standalone valuation and an uncertain deal make risk/reward unpersuasive. Reported bids include AstraZeneca's $124 per share and a rumored Lilly proposal around…

marketbeat.com - Ascendis Pharma A/S (NASDAQ:ASND) EVP Sells 20,000 Shares of Stock
Ascendis Pharma A/S (NASDAQ:ASND) EVP Sells 20,000 Shares of Stock
MarketBeat –

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) EVP Anni Lotte Kirstine Pedersen sold 20,000 shares of the stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $263.89, for a total value of…

thehindubusinessline.com - Anupama Ghosh - Profit-booking drags Nifty below 25,200; Pharma holds firm as metals, durables bleed
Profit-booking drags Nifty below 25,200; Pharma holds firm as metals, durables bleed
The HinduBusinessLine –

Updated - November 18, 2026 at 01:27 PM. Benchmark indices fell sharply in mid-session trade on Wednesday, with broad-based profit-booking accelerating after the morning open. The Sensex was down 624.97 points or 0.76 per cent at 81,907.22 as of…

marketbeat.com - Royalty Pharma (NASDAQ:RPRX) EVP Christopher Hite Sells 100,000 Shares of Stock
Royalty Pharma (NASDAQ:RPRX) EVP Christopher Hite Sells 100,000 Shares of Stock
MarketBeat –

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Christopher Hite sold 100,000 shares of Royalty Pharma stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $68.15, for a total value of $6,815,000.00.

marketbeat.com - Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 232,536 Shares of Company Stock
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 232,536 Shares of Company Stock
MarketBeat –

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) CFO Terrance Coyne sold 232,536 shares of the stock in a transaction on Monday, November 16th. The stock was sold at an average price of $68.87, for a total value of $16,014,754.32. The transaction…

marketbeat.com - Royalty Pharma (NASDAQ:RPRX) Stock Price Target Raised at TD Cowen
Royalty Pharma (NASDAQ:RPRX) Stock Price Target Raised at TD Cowen
MarketBeat –

Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its price target hoisted by stock analysts at TD Cowen from $68.00 to $80.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a 'buy' rating on the…

marketbeat.com - Spyglass Pharma (NASDAQ:SGP) Stock: Insider Ra Capital Management, L.P. Buys 1,000 Shares
Spyglass Pharma (NASDAQ:SGP) Stock: Insider Ra Capital Management, L.P. Buys 1,000 Shares
MarketBeat –

Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) Director Ra Capital Management, L.P. bought 1,000 shares of Spyglass Pharma stock in a transaction dated Monday, November 16th. The stock was acquired at an average cost of $32.43 per share, for…

themeasure.net - Eleanor Semeraro - SAGE Says: The Power of Purpose in Pharma Advertising
SAGE Says: The Power of Purpose in Pharma Advertising
The Measure –

The pharmaceutical category is one of the most prolific TV advertisers, spending billions of dollars annually across linear and streaming CTV. We asked iSpot SAGE to dig up some of the most effective non-OTC pharma ads from the second half of this…

marketbeat.com - Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25
MarketBeat –

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) has received an average rating of 'Moderate Buy' from the six brokerages that are covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, three have…

marketbeat.com - BridgeBio Pharma, Inc. $BBIO Shares Newly Bought by Aberdeen Group plc
BridgeBio Pharma, Inc. $BBIO Shares Newly Bought by Aberdeen Group plc
MarketBeat –

Aberdeen Group plc purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 301,848 shares of the…

marketbeat.com - Avalyn Pharma (NASDAQ:AVLN) Share Price Crosses Below Fifty Day Moving Average on Analyst Downgrade
Avalyn Pharma (NASDAQ:AVLN) Share Price Crosses Below Fifty Day Moving Average on Analyst Downgrade
MarketBeat –

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) shares passed below its 50-day moving average during trading on Tuesday after Morgan Stanley lowered their price target on the stock from $57.00 to $53.00. The stock has a 50-day moving average of…

seekingalpha.com - Albert Anthony - One Liberty Properties: Upgrade After Q3, As Industrial Portfolio Grows Selectively
One Liberty Properties: Upgrade After Q3, As Industrial Portfolio Grows Selectively
Seeking Alpha –

Albert Anthony is the pen name of a business author on Amazon and a contributing analyst to investing platforms like Seeking Alpha since 2023, where he has over + 2,000 followers and has covered hundreds of stocks in multiple sectors including…

afr.com - Joyce Moullakis - Nuix takeover offer caps off a wild six-year rollercoaster ride
Nuix takeover offer caps off a wild six-year rollercoaster ride
Australian Financial Review –

It's almost exactly six years since Nuix debuted on the ASX with much fanfare, and now it looks as though the analytics and intelligence software group will be plucked off the exchange in the coming months. The Macquarie-backed business is just the…

seekingalpha.com - ALLKA Research - Pfizer: The Patent Cliff Fears Are Overblown
Pfizer: The Patent Cliff Fears Are Overblown
Seeking Alpha –

Pfizer Inc., a Big Pharma player offering a 5.96% dividend yield, remains a controversial choice among long-term retail investors. Most concerns reflect PFE's upcoming patent expiration cycle, which is expected to last about 3 years. However, I…

Receive a Daily briefing on Pharma Industry News

Get Started